NCT02346448

Brief Summary

One of the major elements of successful endoscopic retrograde cholangiopancreatography ( ERCP) is the timely and uncomplicated cannulation of the common bile duct (CBD) . Various factors may adversely affect the cannulation procedure of the CBD leading to complications (acute pancreatitis after ERCP, perforation of the duodenum , bleeding ). Endoscopic sphincterotomy is frequently required for interventional procedures (eg stone extraction). During sphincterotomy, incision of the orifice of the papilla will be performed by using a sphincterotome. Complications due to sphincterotomy are known: Bleeding, increased rates of acute pancreatitis, small bowel perforation and scarring with consecutive stenosis of the papilla. As an alternative to sphincterotomy, balloon dilatation using balloon catheters can be performed. As a result, bleeding complications and scarring as late effects might be prevented. Current data is limited in terms of the risk of acute pancreatitis after ERCP when using a balloon catheter. This study aims to evaluate the incidence of acute pancreatitis and other complications after ERCP. Balloon dilatation of the papilla will be prospectively compared with endoscopic sphincterotomy in a randomized multicenter setting.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 20, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 27, 2015

Completed
5 days until next milestone

Study Start

First participant enrolled

February 1, 2015

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

February 12, 2019

Status Verified

February 1, 2019

Enrollment Period

4.8 years

First QC Date

January 20, 2015

Last Update Submit

February 10, 2019

Conditions

Keywords

endoscopic sphincterotomyballoon dilationadverse eventspancreatitisbleeding

Outcome Measures

Primary Outcomes (1)

  • acute pancreatitis

    Definition of acute pancreatitis: Serum lipase or amylase obtained 2 to 6 hours following ERCP + onset of abdominal pain after ERCP persisting for 24h+ need for analgesia

    one to 10 days

Secondary Outcomes (3)

  • severity of pancreatitis using the Imrie score system (according to Imrie et al.)

    one to 10 days

  • endoscopic perforation

    one to two days

  • major bleeding

    one to two days

Study Arms (3)

endoscopic sphincterotomy

ACTIVE COMPARATOR

performing endoscopic sphincterotomy of papilla of Vater during ERCP Device: standard sphincterotome

Procedure: endoscopic sphincterotomy

balloon dilatation for 3 minutes

ACTIVE COMPARATOR

Balloon dilatation of papilla of Vater for 3 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10mm size)

Procedure: balloon dilatation for 3 minutes

balloon dilatation for 6 minutes

ACTIVE COMPARATOR

Balloon dilatation of papilla of Vater for 6 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10 mm size)

Procedure: balloon dilatation for 6 minutes

Interventions

sphincterotomy during ERCP

endoscopic sphincterotomy

balloon dilatation during ERCP using 10mm balloon

balloon dilatation for 3 minutes

balloon dilatation during ERCP using 10mm balloon

balloon dilatation for 6 minutes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • independent indication for ERCP
  • age ≥ 18 years
  • patient is able to understand informed consent

You may not qualify if:

  • S/p sphincterotomy
  • pancreatic or CBD-stent in situ
  • pregnant patient
  • known chronic pancreatitis
  • acute pancreatitis prior to intervention

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Department of Gastroenterology, University Medical Center

Göttingen, Lower Saxony, 37075, Germany

RECRUITING

HELIOS Albert-Schweitzer Hospital Northeim

Northeim, Lower Saxony, 37154, Germany

RECRUITING

HELIOS Klinikum Erfurt

Erfurt, Thuringia, 99089, Germany

RECRUITING

MeSH Terms

Conditions

PancreatitisHemorrhage

Interventions

Sphincterotomy, Endoscopic

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Biliary Tract Surgical ProceduresDigestive System Surgical ProceduresSurgical Procedures, OperativeEndoscopy, GastrointestinalEndoscopy, Digestive SystemEndoscopyMinimally Invasive Surgical ProceduresSphincterotomyMyotomy

Study Officials

  • Tobias Meister, PDDr.med.

    Helios Albert-Schweitzer-Hospital

    STUDY DIRECTOR
  • Volker Ellenrieder, ProfDr.med.

    University Medical Center Göttingen

    STUDY DIRECTOR

Central Study Contacts

Tobias Meister, PDDr.med.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 20, 2015

First Posted

January 27, 2015

Study Start

February 1, 2015

Primary Completion

December 1, 2019

Study Completion

December 1, 2020

Last Updated

February 12, 2019

Record last verified: 2019-02

Locations